Biologics Supplier for Orthopedic Practices in Harrisburg, PA

How orthopedic groups typically qualify a biologics vendor

Orthopedic practices and ambulatory surgery centers generally build vendor qualification into their own compliance process before adding a new supplier to an approved list. That process usually involves reviewing a supplier's registration and licensure documentation, requesting lot-specific records for any product under consideration, and confirming that the supplier's sourcing and testing practices are documented rather than asserted.

Precision Biologics makes a certificate of analysis, a donor eligibility summary, and a lot release record available on request for each lot, so a practice's compliance or risk team can complete its own review without relying on marketing claims.

• Certificate of analysis
• Donor eligibility summary
• Lot release record
• Third-party sterility testing summary

NPI-verified accounts and ordering

Orders are limited to licensed healthcare professionals. Setting up an account requires a valid National Provider Identifier, and pricing is shared only with verified accounts rather than published publicly.

For a multi-provider orthopedic group, this typically means one account administrator coordinates verification for the practice, then manages ordering across providers from a single record.

Receiving cryopreserved shipments in the Northeast

Cryopreserved Wharton's jelly and exosome products are shipped overnight on dry ice in validated containers and stored at -80 degrees Celsius once received. A surgery center or orthopedic practice in the Harrisburg area should have a documented intake process: confirming dry ice presence on arrival, logging the lot number, and placing product into appropriate storage promptly.

Lot-level traceability at the patient record level is maintained on the clinic side, which supports a practice's own recall and quality processes.

Confirming regulatory fit before onboarding

Whether a specific intended use for a tissue allograft or exosome product fits within the framework described in 21 CFR 1271.10 is a determination for the practice and its own counsel, not something Precision Biologics advises on. We recommend Harrisburg-area groups verify their planned use with the Pennsylvania medical board and their own legal counsel before adopting a new product category.

Precision Biologics supports the administrative side of account setup: NPI verification, documentation requests, and peer-to-peer calls focused on product documentation rather than clinical guidance.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.